Enriched milk could lessen gout pain
By Stephen Robinson, 24 January 2012
Gout flare-ups and pain could be reduced by a daily dose of enriched milk, research suggests.
Patients with persistent gout who drank milk infused with dairy extracts had fewer self-reported flare-ups over three months.
The proof-of-concept intervention also reduced pain and improved uric acid excretion.
Earlier studies had suggested that certain components of dairy products, particularly glycomacropeptide (GMP) and G600 milk fat extract (G600), could dampen down the body's inflammatory response to gout crystals.
In the study, patients with recurrent gout symptoms were randomised to three groups to receive either skimmed milk powder enriched with GMP and G600, skimmed milk powder alone, or lactose powder.
Patients mixed their powder with 250ml of water as a vanilla flavoured shake. These were drunk once daily.
Researchers from New Zealand assessed gout pain at baseline and after three months. Patients recorded their progress in a symptom diary. In all, 102 patients finished the study.
All three groups had fewer self-reported gout flare-ups, but this reduction was greatest among those patients on the enriched milk diet, researchers found.
They also saw greater improvements in pain and uric acid content of their urine among those drinking enriched milk than other patients.
There was also a trend towards a reduction in the number of tender joints.
Critically, the enriched skimmed milk diet did not boost weight gain. Nor did it adversely affect renal function, lipid profile or BP, although flatulence, nausea and diarrhoea were reported by all groups.
Authors concluded: 'This is the first reported RCT of dietary intervention in gout management, and suggests that daily intake of skimmed milk powder enriched with GMP and G600 may reduce the frequency of gout flares.'
Featured pain resource - paineurope.com
| Pain management resource for healthcare professionals in Europe
paineurope.com is a promotional resource, funded by and prepared with editorial input from Mundipharma International Ltd, as a service to pain management.
Item Code: MINT/PPR-12008
Date of Preparation: May 2012
- Related Drug Categories
- Related MIMS Tables
- Monitoring Requirements for DMARDs
- Related MIMS Guidelines and Summaries
- Pegloticase for Treating Severe Debilitating Chronic Tophaceous Gout (TA291)
- Abatacept for Treating Rheumatoid Arthritis After the Failure of Conventional Disease-Modifying Anti-Rheumatic Drugs (TA280)
- Tocilizumab for the Treatment of Rheumatoid Arthritis (TA247)
Latest jobs Jobs web feed
- Clinical Research Physician Synexus Ltd Competitive, UK based sites
- Salaried GP DMC Healthcare Competitive Salary, East Dulwich, South London
- Salaried GP The Medical Centre - Kent Competitive, Maidstone, Kent
- Salaried GP Horden Group Practice Salary will be dependant on experience, Horden, County Durham
- Locum GP (Liverpool) Agenda Medical Locums £550 - 650 per day, Liverpool
- Locum GP (Newcastle) Agenda Medical Locums £525 per day, Newcastle